$312 Million is the total value of Abingworth LLP's 21 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 5.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $90,711,000 | -9.7% | 4,168,718 | 0.0% | 29.04% | +1.8% | |
| SRRA | Buy | Sierra Oncology | $72,277,000 | +71.6% | 1,314,127 | +0.0% | 23.14% | +93.7% |
| VERA | Vera | $40,289,000 | -41.9% | 2,960,231 | 0.0% | 12.90% | -34.4% | |
| ACET | Adicet | $30,885,000 | -26.7% | 2,115,385 | 0.0% | 9.89% | -17.3% | |
| New | Hillevax | $19,929,000 | – | 1,838,486 | +100.0% | 6.38% | – | |
| PHAT | Phathom | $12,112,000 | -37.9% | 1,435,106 | 0.0% | 3.88% | -29.9% | |
| Jasper | $10,638,000 | -45.5% | 5,628,558 | 0.0% | 3.40% | -38.5% | ||
| VRNA | Buy | Veronasponds adr | $10,174,000 | -16.2% | 2,457,500 | +0.0% | 3.26% | -5.4% |
| eFFECTOR | $6,462,000 | -65.8% | 4,822,114 | 0.0% | 2.07% | -61.4% | ||
| RPHM | Reneo | $5,413,000 | -10.9% | 2,073,957 | 0.0% | 1.73% | +0.5% | |
| SLNO | Soleno | $3,165,000 | -20.2% | 18,022,602 | 0.0% | 1.01% | -10.0% | |
| Spruce Bio | $3,101,000 | -13.1% | 1,792,518 | 0.0% | 0.99% | -1.9% | ||
| NCNA | Nucanaadr | $2,417,000 | -26.3% | 3,333,333 | 0.0% | 0.77% | -16.9% | |
| PRTK | Paratek | $1,999,000 | -35.1% | 1,041,131 | 0.0% | 0.64% | -26.8% | |
| SIEN | Sell | Sientra | $1,389,000 | -73.3% | 1,673,589 | -28.8% | 0.44% | -69.8% |
| XCUR | Sell | Exicure | $594,000 | -56.5% | 281,636 | -96.0% | 0.19% | -51.0% |
| CBAY | Cymabay | $385,000 | -5.2% | 131,036 | 0.0% | 0.12% | +7.0% | |
| MTEM | Molecular Templates | $182,000 | -73.6% | 200,000 | 0.0% | 0.06% | -70.4% | |
| OBSV | Obseva | $141,000 | +6.0% | 87,999 | 0.0% | 0.04% | +18.4% | |
| AGLE | Aeglea | $121,000 | -78.1% | 240,500 | 0.0% | 0.04% | -75.2% | |
| HSGX | Ocugen | $16,000 | -30.4% | 7,111 | 0.0% | 0.01% | -28.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.